Tiocarlide

drugbox
IUPAC_name = 1,3-bis [4-(3-methylbutoxy)phenyl] thiourea

---

CAS_number = 910-86-1
ATC_prefix = J04
ATC_suffix = AD02
PubChem = 3001386
DrugBank =
C=23|H=32|N=2|O=2|S=1
molecular_weight = 400.578 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Tiocarlide (or thiocarlide or isoxyl) is a thiourea drug used in the treatment of tuberculosis.

Tiocarlide has considerable antimycobacterial activity "in vitro" and is effective against multi-drug resistant strains of "Mycobacterium tuberculosis". Isoxyl inhibits "M. bovis" with six hours of exposure, which is similar to isoniazid and ethionamide, two other prominent anti-TB drugs. Unlike these two drugs, however, isoxyl also partially inhibits the synthesis of fatty acids.

Tiocarlide was developed by a Belgian company, Continental Pharma S.A. Belgo-Canadienne in Brussels, Belgium. The head researcher was Professor N. P. Buu-Hoi, head of Continental Pharma's Research Division.

References